Cargando…
Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients
Introduction: The prognosis of glioblastoma (GBM) treated with standard-of-care maximal surgical resection and concurrent adjuvant temozolomide (TMZ)/radiotherapy remains very poor (less than 15 months). GBMs have been found to contain a small population of cancer stem cells (CSCs) that contribute t...
Autores principales: | Howard, Candace M., Valluri, Jagan, Alberico, Anthony, Julien, Terrence, Mazagri, Rida, Marsh, Robert, Alastair, Hoyt, Cortese, Antonio, Griswold, Michael, Wang, Wanmei, Denning, Krista, Brown, Linda, Claudio, Pier Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310181/ https://www.ncbi.nlm.nih.gov/pubmed/28199863 http://dx.doi.org/10.1016/j.tranon.2017.01.008 |
Ejemplares similares
-
Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients’ healthcare costs
por: Ranjan, Tulika, et al.
Publicado: (2023) -
Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer()
por: Howard, Candace M., et al.
Publicado: (2020) -
Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer
por: Howard, Candace M, et al.
Publicado: (2021) -
Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series()
por: Ranjan, Tulika, et al.
Publicado: (2020) -
Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial
por: Ranjan, Tulika, et al.
Publicado: (2023)